Skip to main content
Wanbury Limited logo

Wanbury Limited — Investor Relations & Filings

Ticker · WANBURY ISIN · INE107F01022 LEI · 335800QB384KGMBID276 BSE.NS Manufacturing
Open in API
Filings indexed 912 across all filing types
Latest filing 2026-03-24 Regulatory Filings
Country IN India
Listing BSE.NS WANBURY

About Wanbury Limited

https://www.wanbury.com

Wanbury Limited specializes in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and finished formulations. The organization maintains a significant global presence, particularly as a leading producer of Metformin. Its product portfolio spans diverse therapeutic areas, including gynecology, orthopedics, hematinics, and anti-diabetics. The company operates manufacturing facilities compliant with international regulatory standards, including the USFDA. Wanbury focuses on providing medicinal solutions through integrated research and development capabilities and large-scale production infrastructure, serving both domestic and international markets with a range of specialty products.

Recent filings

Filing Released Lang Actions
Press Release
Regulatory Filings Classification · 75% confidence The document is a formal disclosure letter addressed to the National Stock Exchange of India and BSE Limited under Regulation 30(6) of SEBI listing requirements, informing the exchanges of a new pediatric-focused product launch. It does not contain financial results or management discussion, nor is it an AGM, earnings release, proxy, or other specialized form. This falls under a general regulatory announcement (compliance disclosure). Thus it should be classified as a Regulatory Filing (RNS).
2026-03-24 English
Press Release
Regulatory Filings Classification · 95% confidence The document text is extremely short (687 characters) and consists primarily of a digital signature block with no substantive content related to financial results, management changes, or any report. There is no indication of a full report, announcement, or detailed financial data. The content resembles an officer certification or attestation, which typically falls under Regulatory Filings (RNS).
2026-03-12 English
Press release dated 12.03.2026
Regulatory Filings
2026-03-12 English
Reply to Clarification- Financial results
Regulatory Filings Classification · 78% confidence The document is a formal letter and certified board resolution addressed to Indian stock exchanges under SEBI LODR regulations. It responds to a compliance notice, encloses a board resolution approving closure of subsidiaries, and provides the outcome of an August 4 board meeting (including unaudited financial results to be attached). It does not itself contain full financial statements nor is it a pure financial report; rather, it is a regulatory announcement of board actions and report publication. Therefore, it best fits under the general Regulatory Filings (RNS) category.
2026-03-05 English
Investor Presentation on Un-audited Financial Results (UFR) for the quarter and nine months ended 31st December, 2025.
Regulatory Filings
2026-02-09 English
Investor Presentation
Investor Presentation Classification · 95% confidence The document is a detailed slide deck titled “Investors Presentation on Un-audited Financial Results (UFR) for the quarter and nine months ended 31st December 2025” and includes extensive investor-focused content (company profile, financial highlights, strategy, board details). It was filed under SEBI LODR Regulation 30 as an “Investor Presentation.” This matches the definition for an Investor Presentation (Code: IP).
2026-02-09 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.